General Notes
This product (Catalog No. DPABH-26201) is a rabbit-derived polyclonal antibody raised against human VHL, targeting the amino acid region 70–213 of the protein. It has been affinity purified by Protein A. The Von Hippel–Lindau (VHL) tumor suppressor is a protein-coding gene located on the short arm of chromosome 3 (3p25.3) that encodes the VHL protein (pVHL), a key regulator of cellular responses to hypoxia. The pVHL protein serves as the substrate recognition subunit of an E3 ubiquitin ligase complex, which, under normal oxygen levels (normoxia), targets the α-subunits of hypoxia-inducible factors (HIF-α) for ubiquitination and subsequent proteasomal degradation. This process prevents the accumulation of HIF, thereby suppressing the transcription of genes involved in angiogenesis, metabolism, and cell proliferation that are typically activated during low-oxygen conditions (hypoxia). Inactivating germline mutations in the VHL gene cause Von Hippel–Lindau disease, a rare autosomal dominant hereditary cancer syndrome with near-complete penetrance by age 65, predisposing affected individuals to multiple tumors such as central nervous system hemangioblastomas, retinal hemangioblastomas, clear cell renal cell carcinomas, pheochromocytomas, and pancreatic neuroendocrine tumors.
DPABH-26201 is suitable for use in ELISA (1:4,000–1:8,000), IHC (1:50–1:100), Western blot (WB) (1:1,000–1:4,000) applications.
DPABH-26201 is supplied as a liquid formulation in 0.01M PBS, pH 7.4, 50% Glycerol, 0.05% Proclin 300. For long-term storage, keep at −20 °C. For short-term use, store at 2–8 °C. Avoid repeated freeze–thaw cycles to maintain antibody integrity and performance.
COA
Publication 
Loading ......
